HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Differential protective effects of volatile anesthetics against renal ischemia-reperfusion injury in vivo.

AbstractBACKGROUND:
Volatile anesthetics protect against cardiac ischemia-reperfusion injury via adenosine triphosphate-dependent potassium channel activation. The authors questioned whether volatile anesthetics can also protect against renal ischemia-reperfusion injury and, if so, whether cellular adenosine triphosphate-dependent potassium channels, antiinflammatory effects of volatile anesthetics, or both are involved.
METHODS:
Rats were anesthetized with equipotent doses of volatile anesthetics (desflurane, halothane, isoflurane, or sevoflurane) or injectable anesthetics (pentobarbital or ketamine) and subjected to 45 min of renal ischemia and 3 h of reperfusion during anesthesia.
RESULTS:
Rats treated with volatile anesthetics had lower plasma creatinine and reduced renal necrosis 24-72 h after injury compared with rats anesthetized with pentobarbital or ketamine. Twenty-four hours after injury, sevoflurane-, isoflurane-, or halothane-treated rats had creatinine (+/- SD) of 2.3 +/- 0.7 mg/dl (n = 12), 1.8 +/- 0.5 mg/dl (n = 6), and 2.4 +/- 1.2 mg/dl (n = 6), respectively, compared with rats treated with pentobarbital (5.8 +/- 1.2 mg/dl, n = 9) or ketamine (4.6 +/- 1.2 mg/dl, n = 8). Among the volatile anesthetics, desflurane demonstrated the least reduction in plasma creatinine after 24 h (4.1 +/- 0.8 mg/dl, n = 12). Renal cortices from volatile anesthetic-treated rats demonstrated reduced expression of intercellular adhesion molecule 1 protein and messenger RNA as well as messenger RNAs encoding proinflammatory cytokines and chemokines. Volatile anesthetic treatment reduced renal cortex myeloperoxidase activity and reduced nuclear translocation of proinflammatory nuclear factor kappaB. Adenosine triphosphate-dependent potassium channels are not involved in sevoflurane-mediated renal protection because glibenclamide did not block renal protection (creatinine: 2.4 +/- 0.4 mg/dl, n = 3).
CONCLUSION:
Some volatile anesthetics confer profound protection against renal ischemia-reperfusion injury compared with pentobarbital or ketamine anesthesia by attenuating inflammation. These findings may have significant clinical implications for anesthesiologists regarding the choice of volatile anesthetic agents in patients subjected to perioperative renal ischemia.
AuthorsH Thomas Lee, Ayuko Ota-Setlik, Yulei Fu, Samih H Nasr, Charles W Emala
JournalAnesthesiology (Anesthesiology) Vol. 101 Issue 6 Pg. 1313-24 (Dec 2004) ISSN: 0003-3022 [Print] United States
PMID15564938 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • ATP-Binding Cassette Transporters
  • Anesthetics, Inhalation
  • Cytokines
  • Inflammation Mediators
  • KATP Channels
  • NF-kappa B
  • Potassium Channels
  • Potassium Channels, Inwardly Rectifying
  • Proteins
  • Tumor Necrosis Factor-alpha
  • uK-ATP-1 potassium channel
  • Intercellular Adhesion Molecule-1
  • Creatinine
  • Peroxidase
Topics
  • ATP-Binding Cassette Transporters
  • Anesthetics, Inhalation (therapeutic use)
  • Animals
  • Creatinine (blood)
  • Cytokines (biosynthesis, genetics)
  • Electrophoretic Mobility Shift Assay
  • Immunoblotting
  • Inflammation (pathology)
  • Inflammation Mediators (metabolism)
  • Intercellular Adhesion Molecule-1 (metabolism)
  • Ischemia (prevention & control)
  • KATP Channels
  • Kidney (pathology)
  • Kidney Cortex (enzymology)
  • Kidney Diseases (pathology, prevention & control)
  • Kidney Function Tests
  • Male
  • NF-kappa B (metabolism)
  • Necrosis
  • Peroxidase (metabolism)
  • Potassium Channels (agonists)
  • Potassium Channels, Inwardly Rectifying
  • Proteins (metabolism)
  • Rats
  • Rats, Sprague-Dawley
  • Renal Circulation (physiology)
  • Reperfusion Injury (prevention & control)
  • Reverse Transcriptase Polymerase Chain Reaction
  • Tumor Necrosis Factor-alpha (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: